Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 10/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444066 | 0.87 | ALDH1A1 (0.42) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL8338176 | 0.76 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL8537379 | 0.76 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL22349203 | 0.75 | STING1 (0.38) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL903329 | 0.74 | P2RX3 (0.70) | ALDH1A1P2RX3TYMP | |
| SCHEMBL20691336 | 0.73 | RNASEL (0.42) | ALDH1A1P2RX3 | |
| SCHEMBL21539912 | 0.72 | ALDH1A1 (0.45) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20691935 | 0.70 | P2RX3 (0.42) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL9310418 | 0.70 | ALDH1A1 (0.58) | ALDH1A1LMNAALBMAPK1P2RX3 | |
| SCHEMBL20691298 | 0.70 | AHCY (0.37) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | ALDH1A1 1444/4885LMNA 1855/4885ALB 4882/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | ALDH1A1 1444/4885LMNA 1855/4885ALB 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.